

ATTY. DOCKET	: 17679 (BOT)	SERIAL NO.: 10/789,180
APPLICANT:	Catherine Turkel et al.	TITLE: METHODS FOR TREATING PAIN AND FOR TREATING A MEDICATION OVERUSE DISORDER
FILING DATE:	February 26, 2004	GROUP:

#### **U.S. PATENT DOCUMENTS**

*EXAMINER		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
1/4	AA	10/194,805		Donovan, Stephen			7/11/2002
	AB	10/423,380		Ackerman, Alan H.			4/25/2003
	AC	10/429,069		Voet, Martin A.			5/2/2003
	AD	10/630,587		Aoki et al.			7/29/2003
	AE	10/731,973		First, Eric R.			12/9/2003
	AF	10/752,869		First, Eric R.			1/6/2004
	AG	60/418,789		Katz, Howard			10/15/2002
	AH	2003 0224019	12/4/2003	Christopher O'Brien			
	Al	5,437,291	8/1/1995	Pasricha et al.			
	AJ	5,670,484	9/23/1997	William J. Binder			
	AK	5,714,468	2/3/1998	William J. Binder			
	AL	5,766,605	6/16/1998	Sanders et al.			
	AM	5,989,545	11/23/1999	Foster et al.			
	AN	6,063,768	5/16/2000	Eric R. First			
	AO	6,139,845	10/31/2000	Stephen Donovan			
	AP	6,299,893	10/9/2001	Schwartz et al.			
	AQ	6,306,423	10/23/2001	Donovan et al.			
	AR	6,312,708	11/6/2001	Stephen Donovan			
	AS	6,358,917	3/19/2002	Carruthers et al.			
	AT	6,423,319	7/23/2002	Brooks et al.			
	AU	6,447,787	9/10/2002	Gassner et al.			
	AV	6,458,365	10/1/2002	Aoki et al.			
	AW	6,464,986	10/15/2002	Aoki et al.			
	AX	6,623,742	9/23/2003	Martin A. Voet			

EXAMINER Janena Had

DATE CONSIDERED

On Draw line should district if

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ATTY. DOCKET:	17679 (BOT)	SERIAL NO.: 10/789,180
APPLICANT: C	atherine Turkel et al.	TITLE: METHODS FOR TREATING PAIN AND FOR TREATING A MEDICATION OVERUSE DISORDER
FILING DATE:	February 26, 2004	GROUP:

### FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
	ВА	DE 101 50 415	5/15/2003	Germany			N
1 , 1	_	A1 -				i	
MAT	вк	WO 03/011333	2/13/2003	PCT			Y

## OTHER ART

(Including Author, Title, Date, Pertinent Pages, etc.)

		(including Adinor, Title, Date, Fernich Lages, etc.)
M	CA	Aoki K., et al, Mechanisms of the antinociceptive effect of subcutaneous Botox: Inhibition of peripheral and central nociceptive processing, Cephalalgia 2003 Sep;23(7):649
	Aoki, K., et al., Botulinum toxin type A and other botulinum toxin serotypes. comparative review of biochemical and pharmacological actions, Eur J. Ne 2001: (suppl 5); 21-29	
	CC	Aoki, K., <i>Physiology and pharmacology of therapeutic botulinum neurotoxins</i> , in Kreyden, O., editor, Hyperhydrosis and botulinum toxin in dermatology, Basel, Karger; 2002; 30: pages 107-116, at 109-110
	CD	Bhattacharya K., et al., Novel uses of botulinum toxin type A: two case reports, Mov Disord 2000; 15(Suppl 2):51-52
	CE	Bigalke H., et al., Botulinum A Neurotoxin Inhibits Non-Cholinergic Synaptic Transmission in Mouse Spinal Cord Neurons in Culture, Brain Research 360;318- 324:1985
	CF	Bigalke H., et al., Tetanus Toxin and Botulinum A Toxin Inhibit Release and Uptake of Various Transmitters, as Studied with Particulate Preparations From Rat Brain and Spinal Cord, Naunyn-Schmiedeberg's Arch Pharmacol 316;244-251:1981
	CG	Binz T. et al., The Complete Sequence of Botulinum Neurotoxin Type A and Comparison with Other Clostridial Neurotoxins, J Biological Chemistry 265(16);9153-9158:1990
V	СН	Blugerman G., et al., Multiple eccrine hidrocystomas: A new therapeutic option with botulinum toxin, Dermatol Surg 2003 May;29(5):557-9

EXAMINER

DATE CONSIDERED

Drow line through situation if

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ATTY. DOCKET	: 17679 (BOT)	SERIAL NO.: 10/789,180
APPLICANT:	Catherine Turkel et al.	TITLE: METHODS FOR TREATING PAIN AND FOR TREATING A MEDICATION OVERUSE DISORDER
FILING DATE:	February 26, 2004	GROUP:

M CI	Brem, H., et al, <i>Placebo-Controlled Trial of Safety and Efficacy of Intraoperative Controlled Delivery by Biodegradable Polymers of Chemotherapy for Recurrent Gliomas</i> , Lancet 345;1008-1012:1995
(   a	Brin, M., et al., Botulinum toxin type A: pharmacology, in Mayer N., editor, Spasticity: etiology, evaluation, management and the role of botulinum toxin, 2002; pages 110-124, at 112-113
СК	Bushara K., Botulinum toxin and rhinorrhea, Otolaryngol Head Neck Surg 1996;114(3):507
CL	Cui, M., et al., Mechanisms of the antinociceptive effect of subcutaneous BOTOX®: inhibition of peripheral and central nociceptive processing, Naunyn Schmiedebergs Arch Pharmacol 2002; 365 (supp 2): R17
СМ	Dabrowski et al.; Botulinum toxin as a novel treatment for self mutilation in Lesch- Nyhan syndrome, Ann Neurol 2002 Sep;52(3 Supp 1):S157
CN	Duggan et al.; A surbey of Botulinum neurotoxin substrate expression in cells; Mov Disord, 10(3):376:1995
СО	Fung L. K. et al., Pharmacokinetics of Interstitial Delivery of Carmustine 4- Hydroperoxycyclophosphamide and Paclitaxel From a Biodegradable Polymer Implant in the Monkey Brain, Cancer Research 58;672-684:1998
CP	Gonelle-Gispert et al.; snap-25a and -25b isoforms are both expressed in insulin- secreting cells and can function in insulin secretion; <i>Biochem J 1;339 (pt 1):159-</i> 65:1999
CQ	Guyton A.C. et al., <i>Textbook of Medical Physiology</i> , W.B. Saunders Company 1996, ninth edition; 686-688
CR	Habermann E., et al., <i>Tetanus Toxin and Botulinum A and C Neurotoxins Inhibit Noradrenaline Release From Cultured Mouse Brain</i> , J Neurochem 51(2);522-527:1988
CS	Habermann E., Inhibition by Tetanus and Botulinum A Toxin of the release of [3H]Noradrenaline and [3H]GABA From Rat Brain Homogenate, Experientia 44;224-226: 1988
СТ	Habermann, I-Labeled Neurotoxin from Clostridium Botulinum A: Preparation, Binding to Synaptosomes and Ascent to the Spinal Cord; Nauyn-Schmiedeberg's Arch./Pharmacol. 1974; 28/1/47-56,

**EXAMINER** 

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ATTY. DOCKET	: 17679 (BOT)	SERIAL NO.: 10/789,180
APPLICANT:	Catherine Turkel et al.	TITLE: METHODS FOR TREATING PAIN AND FOR TREATING A MEDICATION OVERUSE DISORDER
FILING DATE:	February 26, 2004	GROUP:

	11		
7	1	CU	Harrison's Principles of Internal Medicine (1998), edited by Anthony Fauci et al.,
		4	14 <sup>th</sup> edition, published by McGraw Hill
1		CV	Heckmann M., et al., Botulinum toxin type A injection in the treatment of lichen
	<u></u>		simplex: An open pilot study, J Am Acad Dermatol 2002 Apr;46(4):617-9
	<b>\</b>	CW	Jacks, L., et al., Idiopathic toe walking: Treatment with botulinum toxin A injection,
1	1		Dev Med Child Neurol 2002;44(Suppl 91):6), and foot dystonia (Rogers J., et al.,
		<u> </u>	Injections of botulinum toxin A in foot dystonia, Neurology 1993 Apr;43(4 Suppl 2
		CX	Jahanshahi M., et al., Psychological functioning before and after treatment of
1 .1			torticollis with botulinum toxin, J Neurol Neurosurg Psychiatry 1992; 55(3): 229-231
		CY	Jankovic J. et al., Therapy With Botulinum Toxin, Marcel Dekker, Inc., (1994), page
1 1		1	5, 150
		CZ	Jost W., Ten years' experience with botulinum toxin in anal fissure, Int J Colorectal
			Dis 2002 Sep;17(5):298-302
		CAA	Katsambas A., et al., Cutaneous diseases of the foot: Unapproved treatments, Clin
		1	Dermatol 2002 Nov-Dec;20(6):689-699
		CBB	Li Y, et al., Sensory and motor denervation influences epidermal thickness in rat
			foot glabrous skin, Exp Neurol 1997;147:452-462 (see page 459)
		CCC	Marjama-Lyons, J., et al., Tremor-Predominant Parkinson's Disease, Drugs & Aging
			16(4);273-278:2000
		CDD	Moyer E et al., Botulinum Toxin Type B: Experimental and Clinical Experience,
		1	being chapter 6, pages 71-85 of "Therapy With Botulinum Toxin", edited by
			Jankovic, J. et al. (1994), Marcel Dekker, Inc.
		CEE	Murry T., et al., Spasmodic dysphonia; emotional status and botulinum toxin
			treatment, Arch Otolaryngol 1994 Mar; 120(3): 310-316
		CFF	Naumann et al; Botulinum toxin type A in the treatment of focal, axillary and palmar
}			hyperhidrosis and other hyperhidrotic conditions; European J. Neurology 6 (Supp
] {			4): S111-S1150:1999
		CGG	Pearce, L.B., Pharmacologic Characterization of Botulinum Toxin For Basic Science
			and Medicine, Toxicon 35(9);1373-1412 at 1393
		СНН	Hagona et al., Management of Parotid Sialocele With Botulinum Toxin; The
<u>                                     </u>			Laryngoscope 109:1344-1346/1999
- 3		СП	Sanchez-Prieto, J., et al., Botulinum Toxin A Blocks Glutamate Exocytosis From
	$\bigvee$		Guinea Pig Cerebral Cortical Synaptosomes, Eur J. Biochem 165;675-681:1897

EXAMINER / / MUMA / DATE CONSIDERED 09/10/04

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ATTY. DOCKET: 17679 (BOT)	SERIAL NO.: 10/789,180
APPLICANT: Catherine Turkel et al.	TITLE: METHODS FOR TREATING PAIN AND FOR TREATING A MEDICATION OVERUSE DISORDER
FILING DATE: February 26, 2004	GROUP:

01	11		
7//	1/	Cii	Schantz, E.J., et al, Properties and use of Botulinum toxin and Other Microbial
'"	/U		Neurotoxins in Medicine, Microbiol Rev. 56;80-99:1992
,	1	СКК	Sevim, S., et al., Botulinum toxin-A therapy for palmar and plantar hyperhidrosis,
L			Acta Neurol Belg 2002 Dec;102(4):167-70
		CLL	Singh, Critical Aspects of Bacterial Protein Toxins, pages 63-84 (chapter 4) of
			Natural Toxins II, edited by B.R. Singh et al., Plenum Press, New York (1976
		СММ	Suputtitada, A., Local botulinum toxin type A injections in the treatment of spastic
			toes, Am J Phys Med Rehabil 2002 Oct;81(10):770-5
		CNN	Weigand et al.; I-Labelled Botulinum A Neurotoxin: Pharmacokinetics in Cats after
			Intramuscular Injection; Nauny-Schmiedeberg's Arch. Pharmacol. 1976; 292, 161-
			165
		COO	Woolf C. et al., Neuropathic Pain: Aetiology, Symptoms, Mechanisms, and
	$\vee$		Management, Lancet 1999; 353: 1959-64

**EXAMINER** 

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.